| Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).J Clin Oncol | PMID 35192411PMC9851689 | 2022-Jun-10 | 0.95 | The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and original result. However, the primary endpoint is a response rate (CR rate), not a time-to-event endpoint. No time-to-event data or analysis (Kaplan-Meier, HR, etc.) are mentioned in the abstract. Therefore, it is excluded. | 待处理 |
| Efficacy and safety of HLX01 in patients with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a phase 3 study.Arthritis Res Ther | PMID 35689239PMC9185960 | 2022-Jun-10 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Intramuscular AZD7442 (Tixagevimab-Cilgavimab) for Prevention of Covid-19.N Engl J Med | PMID 35443106PMC9069994 | 2022-Jun-09 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes from a mechanistic biomarker multi-arm and randomised study of liposomal MTP-PE (Mifamurtide) in metastatic and/or recurrent osteosarcoma (EuroSarc-Memos trial).BMC Cancer | PMID 35672690PMC9175372 | 2022-Jun-08 | 0.90 | The record describes a Phase II randomized trial with a drug intervention (liposomal MTP-PE) and is an original report, but it does not meet the required Phase III/IIIb or Phase II/III designation, and it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.) as the report focuses on feasibility and design, with no efficacy results. | 待处理 |
| Efficacy of HP-3070, an Asenapine Transdermal System, on Symptoms of Hostility in Adults With Schizophrenia: A Post Hoc Analysis of a 6-Week Phase 3 Study.J Clin Psychiatry | PMID 35687858无 PMCID | 2022-Jun-06 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.Lancet | PMID 35644166无 PMCID | 2022-Jun-04 | 0.96 | 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。 | 待处理 |
| Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults.N Engl J Med | PMID 35507481PMC9127771 | 2022-Jun-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine.N Engl J Med | PMID 35507508PMC9127773 | 2022-Jun-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.N Engl J Med | PMID 35569035无 PMCID | 2022-Jun-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Hypericum and neem oil for dehisced post-surgical wounds: a randomised, controlled, single-blinded phase III study.J Wound Care | PMID 35678785无 PMCID | 2022-Jun-02 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Patterns of Relapse After Adjuvant Chemoradiation for Cervical Cancer in a Phase 3 Clinical Trial (PARCER): An Evaluation of Updated NRG Oncology/RTOG Target Delineation Guidelines.Int J Radiat Oncol Biol Phys | PMID 35157993无 PMCID | 2022-Jun-01 | 0.85 | The study is an original result from a phase 3 randomized trial in human cervical cancer, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) with Kaplan-Meier or HR. It focuses on patterns of relapse and dose comparisons for radiation planning, not drug efficacy. The drug component (chemoradiation) is part of the trial's overall regimen, but this specific analysis is not evaluating drug intervention efficacy. | 待处理 |
| Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.JAMA Cardiol | PMID 35416910PMC9008564 | 2022-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Association of Quality-of-Life Outcomes in Cancer Drug Trials With Survival Outcomes and Drug Class.JAMA Oncol | PMID 35482347PMC9052107 | 2022-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.JAMA Neurol | PMID 35532908PMC9086935 | 2022-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rates of Response to Atogepant for Migraine Prophylaxis Among Adults: A Secondary Analysis of a Randomized Clinical Trial.JAMA Netw Open | PMID 35675076PMC9178435 | 2022-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Relugolix Combination Therapy for Uterine Leiomyoma-Associated Pain in the LIBERTY Randomized Trials.Obstet Gynecol | PMID 35675604无 PMCID | 2022-Jun-01 | 0.95 | The study is a definitive Phase III randomized controlled trial in humans with an oncology-related condition (uterine leiomyoma), but the reported outcomes are pain-related efficacy endpoints, not survival, progression, recurrence, death, hazard, or time-to-event outcomes as required by the adjudication criteria. | 待处理 |
| Melatonin Treatment and Adequate Sleep Hygiene Interventions in Children with Autism Spectrum Disorder: A Randomized Controlled Trial.J Autism Dev Disord | PMID 34181143无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ultra-low-dose estradiol and dydrogesterone: a phase III study for vasomotor symptoms in China.Climacteric | PMID 34402360无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.BJU Int | PMID 34480522PMC9423939 | 2022-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| [The role of proton therapy in esophageal cancer].Cancer Radiother | PMID 34688549无 PMCID | 2022-Jun | 0.85 | The record is a review article discussing proton therapy, which is a radiation therapy modality, not a drug intervention. While it mentions randomized trials, it does not present original results from a specific drug-containing Phase III trial with a time-to-event efficacy endpoint. The phase of the trials discussed is not definitively established as Phase III/IIIb from the provided text, and no drug intervention is evident. | 待处理 |
| A Multicenter, Randomized Phase III Study Comparing Platinum Combination Chemotherapy Plus Pembrolizumab With Platinum Combination Chemotherapy Plus Nivolumab and Ipilimumab for Treatment-Naive Advanced Non-Small Cell Lung Cancer Without Driver Gene Alterations: JCOG2007 (NIPPON Study).Clin Lung Cancer | PMID 34802879无 PMCID | 2022-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Immune microenvironment in patients with mismatch-repair-proficient oligometastatic colorectal cancer exposed to chemotherapy: the randomized MIROX GERCOR cohort study.Mol Oncol | PMID 34954864PMC9168761 | 2022-Jun | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Comparison of the Efficacy, Safety, Pharmacokinetic and Immunogenicity of UJVIRA (ZRC-3256, Trastuzumab Emtansine) With the Kadcyla (Trastuzumab Emtansine) in the Treatment of HER2-Positive Metastatic Breast Cancer: A Randomized, Open-Label, Multicenter Study in India.Clin Breast Cancer | PMID 34955432无 PMCID | 2022-Jun | 0.80 | The study is a Phase III randomized trial in oncology with a drug intervention and reports primary results. However, it is ineligible because the primary efficacy endpoint is objective response rate (ORR), which is a categorical measure at a fixed timepoint (Week 24), not a time-to-event endpoint. The publication does not report or signal any time-to-event outcome (OS, PFS, DFS, EFS, RFS, TTP), Kaplan-Meier analysis, or hazard ratio. | 待处理 |
| KESTREL and KITE: 52-Week Results From Two Phase III Pivotal Trials of Brolucizumab for Diabetic Macular Edema.Am J Ophthalmol | PMID 35038415无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Reducing asthma attacks in children using exhaled nitric oxide (RAACENO) as a biomarker to inform treatment strategy: a multicentre, parallel, randomised, controlled, phase 3 trial.Lancet Respir Med | PMID 35101183无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase 3, Randomized, Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Neu-BoNT/A in Treatment of Primary Axillary Hyperhidrosis.Aesthetic Plast Surg | PMID 35132458无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus.Diabetes Obes Metab | PMID 35187770PMC9314964 | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial.Ann Rheum Dis | PMID 35210264无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A randomized controlled trial of surgery and postoperative modified FOLFOX6 versus surgery and perioperative modified FOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases: EXPERT study.Langenbecks Arch Surg | PMID 35211831无 PMCID | 2022-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial Results.Gastroenterology | PMID 35227777无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Safety and efficacy of apalutamide in Japanese patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy: Final report for the Japanese subpopulation analysis of the randomized, placebo-controlled, phase III TITAN study.Int J Urol | PMID 35293030PMC9310605 | 2022-Jun | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19.Eur J Clin Invest | PMID 35342931PMC9111659 | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Results of the COMPARE trial of Constraint-induced or Multimodality Aphasia Therapy compared with usual care in chronic post-stroke aphasia.J Neurol Neurosurg Psychiatry | PMID 35396340PMC9148985 | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Enzalutamide in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Asian Multiregional, Randomized Study.Adv Ther | PMID 35397772PMC9123068 | 2022-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Dosing Regimens of Intravitreal Aflibercept for Diabetic Macular Edema Beyond the First Year: VIOLET, a Prospective Randomized Trial.Adv Ther | PMID 35412227PMC9123040 | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Baseline Characteristics and Treatment Response to Ixekizumab Categorised by Sex in Radiographic and Non-radiographic Axial Spondylarthritis Through 52 Weeks: Data from Three Phase III Randomised Controlled Trials.Adv Ther | PMID 35429281PMC9123018 | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Characteristics of patients with lung cancer in clinical practice and their potential eligibility for clinical trials evaluating tyrosine kinase inhibitors or immune checkpoint inhibitors.Cancer Epidemiol | PMID 35429893无 PMCID | 2022-Jun | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study.Eur J Cancer | PMID 35429901无 PMCID | 2022-Jun | 0.96 | 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 | 待处理 |
| Efficacy and Safety of Dapagliflozin According to Frailty in Heart Failure With Reduced Ejection Fraction : A Post Hoc Analysis of the DAPA-HF Trial.Ann Intern Med | PMID 35467935无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial.Lancet Diabetes Endocrinol | PMID 35468321无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Digital remote monitoring plus usual care versus usual care in patients treated with oral anticancer agents: the randomized phase 3 CAPRI trial.Nat Med | PMID 35469070无 PMCID | 2022-Jun | 0.85 | The trial meets criteria for oncology, human, randomized, phase 3, and drug intervention. However, it fails the key eligibility criterion of having a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as defined in the adjudication instructions. The reported endpoints are clinical and patient-centered outcomes, not survival or progression-free survival time-to-event analyses. | 待处理 |
| Effects of everolimus plus minimized tacrolimus on kidney function in liver transplantation: REDUCE, a prospective, randomized controlled study.Rev Esp Enferm Dig | PMID 35469409无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.Lancet Oncol | PMID 35489363PMC10284118 | 2022-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| The efficacy and safety of keverprazan, a novel potassium-competitive acid blocker, in treating erosive oesophagitis: a phase III, randomised, double-blind multicentre study.Aliment Pharmacol Ther | PMID 35505467无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study.Respir Med | PMID 35512458无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.Lancet Neurol | PMID 35525250无 PMCID | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.Lancet Haematol | PMID 35550060无 PMCID | 2022-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.Lancet Oncol | PMID 35576956无 PMCID | 2022-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Evaluation of the Effect of Food on the Pharmacokinetics of SHR6390, An Oral CDK4/6 Inhibitor, in Healthy Volunteers.Drugs R D | PMID 35635717PMC9167418 | 2022-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC.ESMO Open | PMID 35653981PMC9271477 | 2022-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |